Clinical trial · Interventional
Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
Clinical Activity of Icotinib in Patients With Advanced Non-small-cell Lung Cancer Harbouring Uncommon EGFR Mutations: a Single-arm, Prospective, Phase 2 Study
NCT02961270CI-TRIAL-00024781unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in non-small cell lung cancer patients harboring uncommon EGFR mutation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Icotinib | Drug | Icotinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- icotinib
- description
- patients will be administered study drug (icotinib) until disease progression or unacceptable toxicity
- interventionNames
- Drug: Icotinib
Primary outcomes (1)
- measure
- progression-free survival
- timeFrame
- 10 months
Secondary outcomes (2)
- measure
- tumor response rate
- timeFrame
- 2 months
- measure
- overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with stage IIIB/IV non-small cell lung cancer * Patients with uncommon epidermal growth factor receptor (EGFR) mutation * Targeted-therapy-naive patients * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 * Evaluable target lesions according to RECIST 1.1 for tumour response assessment Exclusion Criteria: * Wild-type EGFR * Positive 19 del and/or 21 L858R mutation * Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib * Patients who have documented history of interstitial lung disease
References
Publications (0)
Data not yet available
No reference posted for this study.